The safety profile of ciclesonide in the treatment of persistent asthma

Allergy and Asthma Proceedings

Volumn 30, Issue 3, 2009, Pages 315-324

  Craig, Timothy ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Asthma; Ciclesonide; Growth; Hypothalamic pituitary adrenal axis; Inhaled corticosteroid; Oral candidiasis; Oropharyngeal adverse events; Safety; Systemic adverse events

Indexed keywords

BUDESONIDE; CICLESONIDE; DEXAMETHASONE; FLUTICASONE PROPIONATE; PLACEBO; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SAFETY; DYSPHONIA; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; MORNING DOSAGE; PHARYNGITIS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SORE THROAT; THRUSH; TREATMENT OUTCOME; VOICE CHANGE; IMMUNOLOGY;

ANTI-ALLERGIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNENEDIONES;

EID: 68249152619     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3224     Document Type: Review

References (76)

1. National Center for Health Statistics. Asthma Prevalence, Health Care Use and Mortality: United States, 2003-05. Available online at www.cdc.gov/nchs/ products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm; last accessed December 2006.
2. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Programme. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available online at www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. 2007; last accessed October 2007.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2006. Available online at www.ginasthma.org; last accessed November 2006.
4. Horak E, Sawyer SM, Roberts M, et al. Impact of disease severity on quality of life in adults with asthma. Wien Klin Wochenschr 117:462-467, 2005.
5. Lenney W. The burden of pediatric asthma. Pediatr Pulmonol Suppl 15:13-16. 1997.
6. Nocon A, and Booth T. The social impact of asthma. Fam Pract 8:37-41, 1991.
7. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: The global asthma insights and reality surveys. J Allergy Clin Immunol 114:40-47, 2004.
8. Blanc PD, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: Findings from a population-based survey. J Clin Epidemiol 54:610-618, 2001.
9. Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 145:890-899, 1992.
10. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332-336, 2000.
11. Sin DD, and Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 162:1591-1595, 2002.
12. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53, 1998.
13. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669-674, 1992.
14. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 61:518-526, 2006.
15. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100:1307-1317, 2006.
16. Canonica GW, Baena-Cagnani CE, Blaiss MS, et al. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: Global adult findings. Allergy 62:668-674, 2007.
17. Rachelefsky GS, Liao Y, and Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: Results from a meta-analysis. Ann Allergy Asthma Immunol 98:225-238, 2007.
18. Reed CE. Inhaled corticosteroids: Why do physicians and patients fail to comply with guidelines for managing asthma? Mayo Clin Proc 79:453-455, 2004.
19. Roland NJ, Bhalla RK, and Earis J. The local side effects of inhaled corticosteroids: Current understanding and review of the literature. Chest 126:213-219, 2004.
20. Leach C, Bethke T, and Boudreau R. 2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers. J Aerosol Med 19:117-126, 2006.
21. Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide. J Allergy Clin Immunol 111:S380, 2003 (Abs 598).
22. Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100:375-384, 2006.
23. Engelstaetter R, Banerji D, Steinijans V, et al. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: Results from a pooled analysis. Am J Respir Crit Care Med 169:A72, 2004 (Abs 37).
24. Banerji D, Szwarcberg J, Fish J, et al. The incidence of oropharyngeal adverse events in adolescent/adults and pediatric asthma patients is similar for ciclesonide and placebo: Results from pooled analyses. Allergy Asthma Proc 25:P206, 2004.
25. Dietzel K, Engelstatter R, and Keller A. Ciclesonide: An on-site activated steroid. Prog Respir Res 31:91-93, 2001.
26. Nave R, Zech K, and Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 61:203-208, 2005.
27. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45:146-152, 2005.
28. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clin Ther 27:1752-1763, 2005.
29. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17:1083-1088, 2001.
30. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99:1275-1285, 2005.
31. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60:330-337, 2005.
32. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 19:404-412, 2006.
33. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116:1206-1212, 2005.
34. Berger WE, Kerwin E, Bernstein DI, et al. Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc 30:304-314, 2009.
35. Meltzer EO, Korenblat PE, Weinstein SF, et al. Efficacy and safety evaluation of ciclesonide in mild-to-moderate persistent asthma previously treated with inhaled corticosteroids. Allergy Asthma Proc 39:293-303, 2009.
36. Berger W, Galant S, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in adults/adolescents with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 96:140, 2006 (Abs 133).
37. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94:465-472, 2005.
38. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 100:785-794, 2006.
39. Busse W, Kaliner M, Bernstein D, et al. The novel inhaled corticosteroid ciclesonide is efficacious and has a favourable safety profile in adults and adolescents with severe persistent asthma. J Allergy Asthma Immunol 115:S213, 2005 (Abs 846).
40. Korenblat P, Bernstein D, Fish J, et al. Ciclesonide HFA-MDI has a lower incidence of oral candidiasis that beclomethasone dipropionate HFA-MDI in patients with severe persistent asthma: Results of a long-term study. Ann Allergy Asthma Immunol 94:173, 2005 (Abs P171).
41. Agertoft L, and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115:940-945, 2005.
42. Gelfand EW, Georgitis JW, Noonan M, et al. Once-daily ciclesonide in children: Efficacy and safety in asthma. J Pediatr 148:377-383, 2006.
43. Meltzer E, Sotomayor J, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in children with persistent asthma of all severities. Ann Allergy Asthma Immunol 96:140-141, 2006 (Abs 134).
44. Pedersen S, Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 41:954-961, 2006.
45. Rohatagi S, Rhodes GR, and Chaikin P. Absolute oral versus inhaled bioavailability: Significance for inhaled drugs with special reference to inhaled glucocorticoids. J Clin Pharmacol 39:661-663, 1999.
46. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47, 2004.
47. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12:201-209, 2005.
48. Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43:479-486, 2004.
49. Tayab ZR, and Hochhaus G. Advances in single-entity inhaled corticosteroid therapy. Allergy Asthma Proc 28:125-135, 2007.
50. Nave R, Bethke T, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur Respir J 20(suppl 38):P749, 2002.
51. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 47:782-789, 2007.
52. Honour JW. Hypothalamic-pituitary-adrenal axis. Respir Med 88(suppl A):9-13, 1994.
53. Adinoff B, Iranmanesh A, Veldhuis J, et al. Disturbances of the stress response: The role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res World 22:67-72, 1998.
54. Kelly HW, and Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 112:469-478, 2003.
55. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol 112(suppl 3):S1-S40, 2003.
56. Bernstein DI, and Allen DB. Evaluation of tests of hypothalamic- pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 98:118-127, 2007.
57. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87:2160-2163, 2002.
58. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 18:328-336, 2005.
59. Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 28:906-920, 2006.
60. Larsen BB, Nielsen LP, Engelstatter R, et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 58:207-212, 2003.
61. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 127:851-860, 2005.
62. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 128:1104-1114, 2005.
63. Nayak A, Nathan R, Williams J, et al. Ciclesonide does not suppress the hypothalamic-pituitary-adrenal axis function in patients with severe persistent asthma: Results of a long-term study. Ann Allergy Asthma Immunol 94:171-172, 2005 (Abs P164).
64. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 27:1168-1174, 2006.
65. Nootheti S, and Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children. Compr Ophthalmol Update 7:31-39, 2006.
66. Uboweja A, Malhotra S, and Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: A meta-analysis. Fundam Clin Pharmacol 20:305-309, 2006.
67. Chylack L, Gross G, and Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens. J Asthma 45:893-902, 2008.
68. Skoner D, Maspero J, and Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 121:e1-e14, 2008.
69. Zitt MJ. Advances in inhaled corticosteroid pharmacology. Allergy Asthma Proc 28:114-124, 2007.
70. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 114:1288-1293, 2004.
71. Panhuysen CI, Vonk JM, Koeter GH, et al. Adult patients may outgrow their asthma: A 25-year follow-up study. Am J Respir Crit Care Med 155:1267-1272, 1997.
72. Agertoft L, and Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 88:373-381, 1994.
73. Lee DK, Bates CE, Currie GP, et al. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol 93:253-258, 2004.
74. Lipworth BJ and Clark DJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 52(12):1036-1039, 1997.
75. Kerwin E, Chervinsky P, Fish J, et al. Ciclesonide has no effect on hypothalamic-pituitary-adrenal (HPA)-axis at once-daily doses of 80 μg, 160 μg or 320 μg in the treatment of patients with mild-to-moderate asthma. Am J Respir Crit Care Med 169:90, 2004 (Abs).
76. Georgitis J, Galant S, and Lloyd M. Once-daily ciclesonide does not cause HPA-axis suppression in pediatric asthma patients. Ped Critical Care Med 5:511, 2004 (Abs).